Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology
From Basic Research to Advanced Study
- 1st Edition - May 26, 2022
- Imprint: Academic Press
- Editors: Imteyaz Qamar, Pawan Kumar Maurya
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 0 4 6 1 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 4 6 2 - 9
Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more.
Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death.
- Adopts a translational approach and comprehensively covers the basic science, mechanisms and concepts of cardio-oncology
- Outlines the current knowledge of biomarkers in cancer therapy-related cardiotoxicity
- Provides an understanding of the mechanisms of cardiovascular toxicity of various therapies that may lead to the identification of novel targets to reduce vascular complications
Undergraduate, postgraduate and doctoral students. Professional working in the area of Cardiac toxicity with a broad range of cancer treatments, from conventional cytotoxic agents to newer targeted and immune-based therapies
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter 1: Overview of changes in the cardiovascular system
- Abstract
- 1: Introduction
- 2: Circulatory system
- 3: Blood vessels
- 4: Heart valves
- 5: Physiology of heart
- 6: Cardiac cycle
- 7: Heart sounds
- 8: Heart rate
- 9: Blood
- 10: Effects on the cardiovascular system due to various physical/environmental factors
- 11: Conclusion
- References
- Chapter 2: Cardiovascular disease in cancer survivors: Risk and management
- Abstract
- 1: Introduction
- 2: Section 1: Underlying risk factors: Genetic and environmental
- 3: Section 2: Health behaviors: Overweight and obesity, hyperlipidemia, hypertension, insulin resistance, and metabolic syndrome
- 4: Section 3: Management of risk factors
- 5: Conclusion
- References
- Chapter 3: Recent trends in cancer immunotherapy: Pathways and inhibitors
- Abstract
- 1: Introduction
- 2: CTLA-4 and PD-1 pathways
- 3: PI3K/AKT/mTOR signaling pathways
- 4: Concluding remarks
- References
- Chapter 4: Stroke risk assessment and atrial fibrillation (AF) in cancer patients
- Abstract
- 1: Introduction
- 2: Association between cancer and atrial fibrillation (AF)
- 3: Management and treatment modalities of AF
- References
- Chapter 5: Biochemistry of biomarkers in cardiotoxicity induced in chemotherapeutic drugs
- Abstract
- Funding
- Conflict of interest
- Availability of data and materials
- Authors’ contribution
- Ethics approval
- Consent for publication
- 1: Introduction
- 2: Biomarker discovery pipeline
- 3: Prevalence of cancer and its management strategies
- 4: Cardiotoxicity due to anticancer therapy
- 5: Biomarkers and its molecular aspects in cardiotoxicity
- 6: Future challenges and concluding remarks
- References
- Chapter 6: Cardiotoxic effects of tyrosine kinase inhibitors directed against VEGFR
- Abstract
- Acknowledgments
- 1: Tumor angiogenesis
- 2: VEGF signaling pathway in angiogenesis
- 3: VEGF pathway inhibitors for cancer treatment
- 4: Cardiotoxic effects of VEGF pathway inhibitors
- 5: Cardioprotective agents
- 6: Conclusion
- References
- Chapter 7: Critical insights into cardiotoxicity of anthracyclines
- Abstract
- 1: Introduction
- 2: Mechanism underlying anthracycline-induced cardiotoxicity
- 3: Molecular mechanism of DOX-mediated cardiotoxicity
- 4: Physiological functions of the redox system in CV toxicity
- 5: Strategies to limit doxorubicin cardiotoxicity
- 6: Summary
- References
- Chapter 8: Noninvasive cardiovascular imaging techniques
- Abstract
- 1: Introduction
- 2: Echocardiology
- 3: Magnetic resonance imaging (MRI)
- 4: Cardiac computed tomography
- 5: Radionucleotide imaging
- 6: Myocardial perfusion imaging
- 7: Summary
- References
- Chapter 9: Cardiovascular risk induced by radiotherapy
- Abstract
- 1: Introduction
- 2: Cardiotoxicity
- 3: Risk factors
- 4: Physiopathology
- 5: Heart failure (HF)
- 6: Myocardial ischemia
- 7: Systemic arterial hypertension (SAH)
- 8: Arrhythmias
- 9: Thromboembolism
- 10: Cardiotoxicity associated with radiotherapy (RT)
- 11: Recommendations for follow-up after radiotherapy
- 12: Modern radiotherapy techniques
- References
- Chapter 10: Cardiovascular complication from cancer therapy
- Abstract
- 1: Introduction
- 2: Vascular conditions
- 3: Cancer therapy vs atherosclerosis
- 4: Cardiac structural problem
- 5: Cardiac dysfunction and heart failure
- References
- Chapter 11: Novel anticancer drugs related to cardiotoxicity
- Abstract
- 1: Introduction
- 2: Clinically used cardioprotective drugs against cardiotoxicity
- 3: GPCR-targeted cardioprotective strategies against anticancer-induced cardiotoxicity
- 4: Newly identified GPCR agonist against anticancer-mediated cardiotoxicity
- 5: Conclusion
- References
- Chapter 12: Principles of cardiovascular rehabilitation
- Abstract
- 1: Introduction
- 2: Cardiopulmonary stress testing in prehabilitation, habilitation, and rehabilitation
- 3: Cardiopulmonary exercise testing
- 4: CPET protocol
- 5: Oxygen assimilation
- 6: Respiratory switch ratio
- 7: Ventilator anaerobic ratio
- 8: Positive outcomes of cardiac rehabilitation
- 9: Risk factor for prehabilitation
- 10: Phases of cardiac rehabilitation
- 11: Is rehabilitation too late?
- 12: A paradigm shift in cardiopulmonary rehabilitation
- References
- Chapter 13: Hematopoietic stem cell transplantation: Sources of cells, cryopreservation, and applications
- Abstract
- 1: Introduction
- 2: History and evolution of HSC and HSCT
- 3: Sources of HSCs
- 4: Preservation and storage of HSCs
- 5: Applications of HSCT
- 6: Complications of HSCT in recipients
- 7: Summary
- References
- Index
- Edition: 1
- Published: May 26, 2022
- No. of pages (Paperback): 276
- No. of pages (eBook): 276
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780323904612
- eBook ISBN: 9780323904629
IQ
Imteyaz Qamar
Dr. Imteyaz Qamar is working as an assistant professor at School of biotechnology, Gautam Buddha University, Greater Noida, India. His area on interest is Stress biology, and Cancer Genetics
He earned his Ph.D. in Molecular Endocrinology from Chonnam National University, South Korea with an emphasis on gene regulation and physiological function of an androgen receptor corepressor-19kD using mice model. He has written various manuscripts, grants, progress reports, pre-IND protocols, animal protocols and published in well reputed international journals. He has also received various awards such as Brain Korea-21 Best Research presenter award 2007, Bharath Vikas award 2016, Young Scientist Award 2017 & 2019, STE meritorious award 2019 etc. He serves as a member of editorial boards of various peer reviewed journals. He is also a member of the endocrinology society, United States of America (USA).
Affiliations and expertise
Assistant Professor, School of Biotechnology, Gautam Buddha University, Greater Noida, Gautam Buddha Nagar, Uttar Pradesh, IndiaPM
Pawan Kumar Maurya
Prof. Pawan Kumar Maurya is Dean, School of Life Long Learning & Head of Department of Biochemistry, Central University of Haryana, India. He has done a PhD from the University of Allahabad (A Central University), India & post-doctoral training from Universidade Federal de Sao Paulo-UNIFESP, Brazil; Taipei Medical University (TMU) and National Taiwan University (NTU), Taiwan. He has more than 14 years of teaching and research experience. He is working on biochemical diagnostics, nanomedicine, and clinical biochemistry. He has published over 75 research articles in reputed journals. He has also edited of six books published from Elsevier, USA and Springer-Nature, Singapore. He is recipient of prestigious fellowships: Science without Borders (Government of Brazil) and National Science Council, Taiwan.
Affiliations and expertise
Central University of Haryana, Mahendergarh (Haryana), INDIARead Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology on ScienceDirect